| 1. | Clinical analysis of neonatal septicemia caused by klebsiella pneumoniae
新生儿肺炎克雷伯菌败血症临床分析 |
| 2. | Clinical analysis of 51 enteritis children infected pneumonia klebsiella pneumoniae
小儿肺炎克雷伯氏杆菌肠炎51例临床分析 |
| 3. | Clinical analysis of 68 senile pneumonia patients due to klebsiella pneumoniae infection
老年人克雷伯杆菌肺炎68例临床分析 |
| 4. | Preliminary locating study on the resistant genes of multi - resistant klebsiella pneumoniae
多重耐药肺炎克雷伯菌耐药基因的初步定位研究 |
| 5. | Resistant rates of clinical isolate of klebsiella pneumoniae and escherichia coli in fuzhou
福州地区肺炎克雷伯氏菌和大肠埃希氏菌的药敏监测 |
| 6. | Analysis on risk factors and antibiotic resistance of nosocomial pneumonia caused by klebsiella pneumoniae
医院内肺炎克雷伯菌肺炎危险因素及细菌耐药性分析 |
| 7. | Cultures of blood , peritoneal fluid and necrotic aortic wall all grew klebsiella pneumoniae
血液培养，腹水以及坏死的主动脉壁细茵培养，皆长出克雷白氏肺炎杆茵。 |
| 8. | In vitro studies have demonstrated florfenicol activity against enterobacter cloacae , escherichia coli , klebsiella pneumoniae , salmonella typhi , and shigella dysenteriae
试验表明，氟苯尼考还能够抑制阴沟肠杆菌、大肠埃希菌、克雷白氏肺炎菌、伤寒沙门氏菌和志贺氏痢疾杆菌。 |
| 9. | The capsular glycoprotein from klebsiella pneumoniae ( kp ) is main ingredient of biostim , which is an immonumodulating agent produced by roussel corporation , france
肺炎克雷伯菌( klebsiellapneumoniae ， kp )荚膜糖蛋白是一种免疫调节剂，国外已开发为免疫调节药必思添( biostim ) 。 |
| 10. | To combine the results of morphological and physiological identification and the result of biolog system test , the strain w12 was recognized as klebsiella pneumoniae ss pneumoniae , belonging to klebsiella , enterobacteriaceae
结合biolog系统对其进行鉴定，结果确定该菌为肺炎克雷伯氏菌肺炎亚种( klebsiellapneumoniaesspneumoniae ) 。 |
